Islet transplantation for Type 1 diabetes: Where are we now?

Expert Review of Clinical Immunology

Volumn 11, Issue 1, 2014, Pages 59-68

  Ahearn, Aaron J ^a   Parekh, Justin R ^a   Posselt, Andrew M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

glycemic control; hypoglycemic unawareness; immunosuppression; insulin independence; islet transplantation; transplant site; Type 1 diabetes

Indexed keywords

GLUCOSE; INSULIN;

GLUCOSE BLOOD LEVEL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENCE; INSULIN DEPENDENT DIABETES MELLITUS; MINIMALLY INVASIVE PROCEDURE; ORGAN DONOR; PANCREAS ISLET TRANSPLANTATION; PATIENT SELECTION; REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME; DIABETES MELLITUS, TYPE 1; METABOLISM; PANCREAS ISLET; PATHOLOGY; PROCEDURES; TRANSPLANTATION; TRENDS;

DIABETES MELLITUS, TYPE 1; HUMANS; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; TISSUE AND ORGAN HARVESTING;

EID: 84919786043     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2015.978291     Document Type: Review

References (82)

1. Warnock GL, Kneteman NM, Ryan EA, et al. Continued function of pancreatic islets after transplantation in type I diabetes. Lancet 1989;2(8662):570-2
2. Scharp DW, Lacy PE, Santiago JV, et al. Insulin independence after islet transplantation into type I diabetic patient. Diabetes 1990;39(4):515-18
3. Ballinger WF, Lacy PE. Transplantation of intact pancreatic islets in rats. Surgery 1972; 72(2):175-86
4. Hering BJRC. Islet transplantation for patients with type I diabetes. Graft 1999;2: 12-17
5. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000;343(4):230-8
6. Barton FB, Rickels MR, Alejandro R, et al. Improvement in outcomes of clinical islet transplantation: 1999-2010. Diabetes Care 2012;35(7): 1436-45
7. Department of Health and Human Services (DHHS) CfMaMSC. Islet cell transplantation in the context of a clinical trial(effective October 1, 2004). CMS Manual System 100-03. (Section 733): paragraph 260.3 and. 3.1
8. CIT. Available from www.citisletstudy.org/TCITC [Last accessed November 2012]
9. CITS. Availablefrom www.isletstudy.org/CITS [Last accessed October 2014]
10. Ricordi C, Lacy PE, Finke EH, et al. Automated method for isolation of human pancreatic islets. Diabetes 1988;37(4): 413-20
11. Lakey JR, Aspinwall CA, Cavanagh TJ, Kennedy RT. Secretion from islets and single islet cells following cryopreservation. Cell Transplant 1999;8(6):691-8
12. Lakey JR, Warnock GL, Shapiro AM, et al. Intraductal collagenase delivery into the human pancreas using syringe loading or controlled perfusion. Cell Transplant 1999; 8(3):285-92
13. Toso C, Oberholzer J, Ris F, et al. Factors affecting human islet of Langerhans isolation yields. Transplant Proc 2002;34(3): 826-7
14. Ricordi C, Tzakis A, Alejandro R, et al. Detection of pancreatic islet tissue following islet allotransplantation in man. Transplantation 1991;52(6):1079-80
15. Kissler HJ, Niland JC, Olack B, et al. Validation of methodologies for quantifying isolated human islets: an islet cell resources study. Clin Transplant 2010;24(2):236-42
16. Fetterhoff TJ, Cavanagh TJ, Wile KJ, et al. Human pancreatic dissociation using a purified enzyme blend. Transplant Proc 1995;27(6):3282-3
17. Linetsky E, Bottino R, Lehmann R, et al. Improved human islet isolation using a new enzyme blend, liberase. Diabetes 1997; 46(7):1120-3
18. Brandhorst H, Brandhorst D, Hesse F, et al. Successful human islet isolation utilizing recombinant collagenase. Diabetes 2003;52(5):1143-6
19. Bucher P, Mathe Z, Bosco D, et al. Serva collagenase NB1: a new enzyme preparation for human islet isolation. Transplant Proc 2004;36(4):1143-4
20. Barbaro B, Salehi P, Wang Y, et al. Improved human pancreatic islet purification with the refined UIC-UB density gradient. Transplantation 2007; 84(9):1200-3
21. Szot GL, Lee MR, Tavakol MM, et al. Successful clinical islet isolation using a GMP-manufactured collagenase and neutral protease. Transplantation 2009;88(6):753-6
22. Balamurugan AN, Naziruddin B, Lockridge A, et al. Islet product characteristics and factors related to successful human islet transplantation from the Collaborative Islet Transplant Registry (CITR) 1999. 2010. Am J Transplant 2014;14(11):2595-606
23. Froud T, Yrizarry JM, Alejandro R, Ricordi C. Use of D-STAT to prevent bleeding following percutaneous transhepatic intraportal islet transplantation. Cell Transplant 2004;13(1):55-9
24. Villiger P, Ryan EA, Owen R, et al. Prevention of bleeding after islet transplantation: lessons learned from a multivariate analysis of 132 cases at a single institution. Am J Transplant 2005;5(12): 2992-8
25. van der Windt DJ, Echeverri GJ, Ijzermans JN, Cooper DK. The choice of anatomical site for islet transplantation. Cell Transplant 2008;17(9):1005-14
26. Manciu N, Beebe DS, Tran P, et al. Total pancreatectomy with islet cell autotransplantation: anesthetic implications. J Clin Anesth 1999;11(7):576-82
27. Casey JJ, Lakey JR, Ryan EA, et al. Portal venous pressure changes after sequential clinical islet transplantation. Transplantation 2002;74(7):913-15
28. Shapiro AM, Lakey JR, Rajotte RV, et al. Portal vein thrombosis after transplantation of partially purified pancreatic islets in a combined human liver/islet allograft. Transplantation 1995;59(7):1060-3
29. Bhargava R, Senior PA, Ackerman TE, et al. Prevalence of hepatic steatosis after islet transplantation and its relation to graft function. Diabetes 2004;53(5):1311-17
30. Maffi P, Angeli E, Bertuzzi F, et al. Minimal focal steatosis of liver after islet transplantation in humans: a long-term study. Cell Transplant 2005;14(10):727-33
31. Markmann JF, Rosen M, Siegelman ES, et al. Magnetic resonance-defined periportal steatosis following intraportal islet transplantation: a functional footprint of islet graft survival? Diabetes 2003;52(7): 1591-4
32. Venturini M, Angeli E, Maffi P, et al. Liver focal fatty changes at ultrasound after islet transplantation: an early sign of altered graft function? Diabet Med 2010;27(8):960-4
33. Hughes SJ, Davies SE, Powis SH, Press M. Hyperoxia improves the survival of intraportally transplanted syngeneic pancreatic islets. Transplantation 2003; 75(12):1954-9
34. Rafael E, Ryan EA, Paty BW, et al. Changes in liver enzymes after clinical islet transplantation. Transplantation 2003;76(9): 1280-4
35. Davalli AM, Maffi P, Socci C, et al. Insights from a successful case of intrahepatic islet transplantation into a type 1 diabetic patient. J Clin Endocr Metab 2000;85(10):3847-52
36. Moberg L, Johansson H, Lukinius A, et al. Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet 2002;360(9350): 2039-45
37. Desai NM, Goss JA, Deng S, et al. Elevated portal vein drug levels of sirolimus and tacrolimus in islet transplant recipients: local immunosuppression or islet toxicity? Transplantation 2003;76(11):1623-5
38. Schmidt P, Magnusson C, Lundgren T, et al. Low molecular weight dextran sulfate is well tolerated in humans and increases endogenous expression of islet protective hepatocyte growth factor. Transplantation 2008;86(11):1523-30
39. Cabric S, Sanchez J, Lundgren T, et al. Islet surface heparinization prevents the instant blood-mediated inflammatory reaction in islet transplantation. Diabetes 2007;56(8): 2008-15
40. Teramura Y, Iwata H. Improvement of graft survival by surface modification with poly (ethylene glycol)-lipid and urokinase in intraportal islet transplantation. Transplantation 2011;91(3):271-8
41. Matsumoto S, Takita M, Chaussabel D, et al. Improving efficacy of clinical islet transplantation with iodixanol based islet purification, thymoglobulin induction and blockage of IL-1-beta and TNF-alpha. Cell Transplant 2011;20(10):1641-7
42. McCall M, Pawlick R, Kin T, Shapiro AM. Anakinra potentiates the protective effects of etanercept in transplantation of marginal mass human islets in immunodeficient mice. Am J Transplant 2012;12(2):322-9
43. Eason JD, Pascual M, Wee S, et al. Evaluation of recombinant human soluble dimeric tumor necrosis factor receptor for prevention of OKT3-associated acute clinical syndrome. Transplantation 1996; 61(2):224-8
44. Farney AC, Xenos E, Sutherland DER, et al. Inhibition of pancreatic-islet beta-cell function by tumor-necrosis-factor is blocked by a soluble tumor-necrosis-factor receptor. Transplant Proc 1993;25(1):865-6
45. Shapiro AM. State of the art of clinical islet transplantation and novel protocols of immunosuppression. Curr Diab Rep 2011; 11(5):345-54
46. Rajab A. Islet transplantation: alternative sites. Curr Diab Rep 2010;10(5):332-7
47. Barker CF, Markmann JF, Posselt AM, Naji A. Studies of privileged sites and islet transplantation. Transplant Proc 1991; 23(4):2138-42
48. Svensson J, Lau J, Sandberg M, Carlsson PO. High vascular density and oxygenation of pancreatic islets transplanted in clusters into striated muscle. Cell Transplant 2011;20(5):783-8
49. Cantarelli E, Melzi R, Mercalli A, et al. Bone marrow as an alternative site for islet transplantation. Blood 2009;114(20): 4566-74
50. Maffi P, Balzano G, Ponzoni M, et al. Autologous pancreatic islet transplantation in human bone marrow. Diabetes 2013; 62(10):3523-31
51. Tchervenivanov N, Yuan S, Lipsett M, et al. Morphological and functional studies on submucosal islet transplants in normal and diabetic hamsters. Cell Transplant 2002; 11(6):529-37
52. Caiazzo R, Gmyr V, Hubert T, et al. Evaluation of alternative sites for islet transplantation in the minipig: interest and limits of the gastric submucosa. Transplant Proc 2007;39(8):2620-3
53. Wszola M KA, Berman A, et al. Case of successful endoscopic pancreatic islet autotransplantation into gastric submucosa in patient with chronic pancreatitis-preliminary report. 12th Congress of the Cell Transplant Society; 2013
54. Sutherland DE, Radosevich DM, Bellin MD, et al. Total pancreatectomy and islet autotransplantation for chronic pancreatitis. J Am Coll Surg 2012;214(4): 409-24; discussion 24-6
55. Hering BJ, Kandaswamy R, Harmon JV, et al. Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. Am J Transplant 2004;4(3):390-401
56. Gruessner RW, Sutherland DE, Parr E, et al. A prospective, randomized, open-label study of steroid withdrawal in pancreas transplantation-a preliminary report with 6-month follow-up. Transplant Proc 2001; 33(1-2):1663-4
57. Chatenoud L. Chemical immunosuppression in islet transplantation-friend or foe? N Engl J Med 2008;358(11): 1192-3
58. Gallo R, Natale M, Vendrame F, et al. In vitro effects of mycophenolic acid on survival, function, and gene expression of pancreatic beta-cells. Acta Diabetol 2012; 49(Suppl 1):S123-31
59. Froud T, Baidal DA, Faradji R, et al. Islet transplantation with alemtuzumab induction and calcineurin-free maintenance immunosuppression results in improved short-and long-term outcomes. Transplantation 2008;86(12):1695-701
60. Bellin MD, Barton FB, Heitman A, et al. Potent induction immunotherapy promotes long-term insulin independence after islet transplantation in type 1 diabetes. Am J Transplant 2012;12(6):1576-83
61. Zeng Y, Ricordi C, Lendoire J, et al. The effect of prednisone on pancreatic islet autografts in dogs. Surgery 1993;113(1): 98-102
62. Nicolls MR, Gill RG. LFA-1 (CD11a) as a therapeutic target. Am J Transplant 2006; 6(1):27-36
63. Vincenti F, Mendez R, Pescovitz M, et al. A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation. Am J Transplant 2007;7(7): 1770-7
64. Posselt AM, Bellin MD, Tavakol M, et al. Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab. Am J Transplant 2010;10(8):1870-80
65. Korman BD, Tyler KL, Korman NJ. Progressive multifocal leukoencephalopathy, efalizumab, and immunosuppression: a cautionary tale for dermatologists. Arch Dermatol 2009;145(8):937-42
66. Ryan EA, Shandro T, Green K, et al. Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. Diabetes 2004;53(4):955-62
67. Boggi U, Vistoli F, Amorese G, et al. Long-term (5 years) efficacy and safety of pancreas transplantation alone in type 1 diabetic patients. Transplantation 2012;93(8):842-6
68. Gruessner RW, Gruessner AC. The current state of pancreas transplantation. Nat Rev Endocrinol 2013;9(9):555-62
69. Fiorina P, Folli F, Zerbini G, et al. Islet transplantation is associated with improvement of renal function among uremic patients with type I diabetes mellitus and kidney transplants. J Am Soc Nephrol 2003;14(8):2150-8
70. Thompson DM, Meloche M, Ao Z, et al. Reduced progression of diabetic microvascular complications with islet cell transplantation compared with intensive medical therapy. Transplantation 2011; 91(3):373-8
71. Fung MA, Warnock GL, Ao Z, et al. The effect of medical therapy and islet cell transplantation on diabetic nephropathy: an interim report. Transplantation 2007; 84(1):17-22
72. Fiorina P, Folli F, Bertuzzi F, et al. Long-term beneficial effect of islet transplantation on diabetic macro-/microangiopathy in type 1 diabetic kidney-transplanted patients. Diabetes Care 2003;26(4):1129-36
73. Al-Adra DP, Gill RS, Imes S, et al. Single-donor islet transplantation and long-term insulin independence in select patients with Type 1 diabetes mellitus. Transplantation doi:10.1097/TP.0000000000000217; 2014. [Epub ahead of print]
74. Sahraoui A, Jensen KK, Ueland T, et al. Anakinra and tocilizumab enhance survival and function of human islets during culture: implications for clinical islet transplantation. Cell Transplant 2014;23(10):1199-211
75. Takita M, Matsumoto S, Shimoda M, et al. Safety and tolerability of the T-cell depletion protocol coupled with anakinra and etanercept for clinical islet cell transplantation. Clinical Transplant 2012; 26(5):E471-84
76. Kizilel S, Scavone A, Liu X, et al. Encapsulation of pancreatic islets within nano-thin functional polyethylene glycol coatings for enhanced insulin secretion. Tissue Eng Part A 2010;16(7):2217-28
77. Zhi ZL, Kerby A, King AJ, et al. Nano-scale encapsulation enhances allograft survival and function of islets transplanted in a mouse model of diabetes. Diabetologia 2012;55(4):1081-90
78. Tomei AA, Manzoli V, Fraker CA, et al. Device design and materials optimization of conformal coating for islets of Langerhans. Proc Natl Acad Sci USA 2014;111(29): 10514-19
79. Ludwig B, Reichel A, Steffen A, et al. Transplantation of human islets without immunosuppression. Proc Natl Acad Sci USA 2013;110(47):19054-8
80. O'Connell PJ, Cowan PJ, Hawthorne WJ, et al. Transplantation of xenogeneic islets: are we there yet? Curr Diab Rep 2013; 13(5):687-94
81. Merani S, Shapiro AMJ. Current status of pancreatic islet transplantation. Clin Sci 2006;110(6):611-25
82. Posselt A, Stock P. Beta cell replacement therapy. In: American Diabetes Association/JDRF Type 1 Diabetes Sourcebook. Anne Peters, Lori LaffelJane Chiang, Eds p. 65. 2013